Literature DB >> 21739451

Inverse association of IL28B genotype and liver mRNA expression of genes promoting or suppressing antiviral state.

Hiromi Abe1, C Nelson Hayes, Hidenori Ochi, Masataka Tsuge, Daiki Miki, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, Michiaki Kubo, Yusuke Nakamura, Naoyuki Kamatani, Kazuaki Chayama.   

Abstract

High intrahepatic expression levels of interferon stimulated genes (ISGs) in chronic hepatitis C patients are associated with poor response to interferon plus ribavirin combination therapy. Expression levels of 16 genes (OAS1, PKR, MxA, ISG15, RIG-I, TLR8, IRF7, IRF9, NFKBIA, IL28A/IL28B, IL29, IL28RA, IL10RB, IFNAR2, and STAT1) that promote antiviral state and 4 genes (SOCS1, SOCS3, Zc3h12a, and A20) that suppress antiviral state were analyzed using real-time PCR assays in 133 liver biopsy samples from patients infected with genotypes 1 or 2. Expression levels of genes promoting antiviral state were positively correlated with each other but were not correlated with those that suppress antiviral state. Expression levels of some ISGs were inversely associated with common polymorphisms within the IL28B locus. Genes promoting antiviral state were expressed lower (e.g., ISG15, P = 1.42E-12 and MxA, P = 6.40E-11) in individuals with the protective rs12979860 CC genotype, and genes suppressing antiviral state were expressed higher (A20, P = 0.00107 and Zc3h12a, P = 0.00129, respectively), although some ISGs were not significant after the Bonferroni correction. The expression levels of both an antiviral (MxA) and a suppressor (SOCS1) ISG were independent predictors for non-response. These results suggest that rs12979860 genotype may be associated with response to combination therapy through an inverse relationship between antiviral and suppressor ISGs in the liver.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21739451     DOI: 10.1002/jmv.22158

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  13 in total

Review 1.  Genetics of IL28B and HCV--response to infection and treatment.

Authors:  C Nelson Hayes; Michio Imamura; Hiroshi Aikata; Kazuaki Chayama
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-05-29       Impact factor: 46.802

Review 2.  Regnase-1, a rapid response ribonuclease regulating inflammation and stress responses.

Authors:  Renfang Mao; Riyun Yang; Xia Chen; Edward W Harhaj; Xiaoying Wang; Yihui Fan
Journal:  Cell Mol Immunol       Date:  2017-02-13       Impact factor: 11.530

Review 3.  Impact of host and virus genome variability on HCV replication and response to interferon.

Authors:  Cameron J Schweitzer; T Jake Liang
Journal:  Curr Opin Virol       Date:  2013-07-06       Impact factor: 7.090

4.  Hepatic expression levels of interferons and interferon-stimulated genes in patients with chronic hepatitis C: A phenotype-genotype correlation study.

Authors:  M Noureddin; Y Rotman; F Zhang; H Park; B Rehermann; E Thomas; T J Liang
Journal:  Genes Immun       Date:  2015-05-28       Impact factor: 2.676

5.  Functional polymorphisms in NFκB1/IκBα predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese.

Authors:  Dongsheng Huang; Lei Yang; Yehua Liu; Yumin Zhou; Yuan Guo; Mingan Pan; Yunnan Wang; Yigang Tan; Haibo Zhong; Min Hu; Wenju Lu; Weidong Ji; Jian Wang; Pixin Ran; Nanshan Zhong; Yifeng Zhou; Jiachun Lu
Journal:  Hum Genet       Date:  2013-01-16       Impact factor: 4.132

6.  Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients.

Authors:  Tatsuo Miyamura; Tatsuo Kanda; Shingo Nakamoto; Shuang Wu; Keiichi Fujiwara; Fumio Imazeki; Osamu Yokosuka
Journal:  PLoS One       Date:  2011-12-12       Impact factor: 3.240

7.  Influence of genes suppressing interferon effects in peripheral blood mononuclear cells during triple antiviral therapy for chronic hepatitis C.

Authors:  Sayuki Iijima; Kentaro Matsuura; Tsunamasa Watanabe; Koji Onomoto; Takashi Fujita; Kyoko Ito; Etsuko Iio; Tomokatsu Miyaki; Kei Fujiwara; Noboru Shinkai; Atsunori Kusakabe; Mio Endo; Shunsuke Nojiri; Takashi Joh; Yasuhito Tanaka
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

8.  Polymorphisms of NFκB1 and IκBα and Their Synergistic Effect on Nasopharyngeal Carcinoma Susceptibility.

Authors:  Yehua Liu; Fuman Qiu; Lei Yang; Rongrong Yang; Xiaorong Yang; Dongsheng Huang; Wenxiang Fang; Lisha Zhang; Qingping Jiang; Lan Zhang; Yifeng Zhou; Jiachun Lu
Journal:  Biomed Res Int       Date:  2015-06-16       Impact factor: 3.411

9.  Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection.

Authors:  Janett Fischer; Stephan Böhm; Tobias Müller; Heiko Witt; Christoph Sarrazin; Simone Susser; Pascal Migaud; Eckart Schott; Graeme Stewart; Annika Brodzinski; Balazs Fülöp; Florian van Bömmel; Jacob George; Thomas Berg
Journal:  PLoS One       Date:  2013-10-29       Impact factor: 3.240

Review 10.  Host genetic variants in the pathogenesis of hepatitis C.

Authors:  Monika Rau; Katharina Baur; Andreas Geier
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.